Literature DB >> 185062

Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain.

N Andén, M Grabowska.   

Abstract

The effects of yohimbine (3 mg/kg i.p.), phenoxybenzamine (20 mg/kg i.p.) and clonidine (0.1 mg/kg i.p.) on the synthesis and the utilization of dopamine and noradrenaline in the central nervous system of rats were investigated. Dopa accumulation following decarboxylase inhibition and the alpha-methyltyrosine-induced disappearance of the amines were used as the measure of these effects. The synthesis and the utilization of dopamine and noradrenaline were accelerated by yohimbine. Clonidine plus phenoxybenzamine inhibited the synthesis and utilization of dopamine and the combination also partly antagonized the effects of yohimbine on the trunover of dopamine. The effects of the three drugs on the synthesis and utilization of dopamine might be secondary to their actions on alpha-adrenoreceptors of noradrenaline synapses since, at the doses used, yohimbine increases the release of noradrenaline, phenoxybenzamine blocks postsynapptic noradrenaline receptors and clonidine reduces the release of noradrenaline. This hypothesis is supported by the findings that yohimbine and phenoxybenzamine did not change the increased synthesis of dopamine in reserpine-treated rats and that clonidine did not inhibit the increased synthesis of dopamine after axotomy or treatment with reserpine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 185062     DOI: 10.1016/0014-2999(76)90136-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

1.  FLA 136: selective agonist at central alpha-adrenoreceptors mediating changes in the turnover of noradrenaline.

Authors:  N E Andén; M Grabowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-07       Impact factor: 3.000

2.  Influence of noradrenaline denervation on MPTP-induced deficits in mice.

Authors:  T Archer; A Fredriksson
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

3.  Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurochem Res       Date:  2007-08-12       Impact factor: 3.996

4.  Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.

Authors:  C Marin; E Aguilar; M Bonastre
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

5.  R 28935 and prazosin: effects on central and peripheral alpha-adrenoreceptor activity and on blood pressure.

Authors:  N E Andén; C Gomes; B Persson; G Trolin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

6.  6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats.

Authors:  N Rückert; M Bubser; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Presynaptic alpha 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices.

Authors:  A U Trendelenburg; K Starke; N Limberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

8.  Locus coeruleus neuronal activity determines proclivity to consume alcohol in a selectively-bred line of rats that readily consumes alcohol.

Authors:  Charles H K West; Katherine A Boss-Williams; James C Ritchie; Jay M Weiss
Journal:  Alcohol       Date:  2015-09-25       Impact factor: 2.405

Review 9.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

10.  Alpha 2-autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the rat brain in vivo.

Authors:  F Pi; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.